



Biotech Daily

Tuesday November 8, 2022

Daily news on ASX-listed biotechnology companies

- * **ASX UP, BIOTECH DOWN: PARADIGM UP 12%; IMPEDIMED DOWN 12%**
- * **MONASH QPX9003 ANTIBIOTIC 'SAFE, WELL-TOLERATED'**
- * **CARTHERICS, PETER MAC CTH-001 FOR CUTANEOUS T-CELL LYMPHOMA**
- * **CORRECTION: RESPIRI**
- * **RADIOPHARM TO RELEASE 25.6m ASX ESCROW SHARES**
- * **HEALTHCARE 2030, BERGEN, EUGENE TABLIS DOWN TO 10% NUHEARA**
- * **ALTHEA 8.35m M-D JOSHUA FEGAN RIGHTS AGM**

MARKET REPORT

The Australian stock market was up 0.36 percent on Tuesday November 8, with the ASX200 up 25.2 points to 6,958.9 points. Sixteen of the Biotech Daily Top 40 stocks were up, 18 fell and six traded unchanged. All three Big Caps were up.

Paradigm was the best, up 18 cents or 12.2 percent to \$1.65, with 1.5 million shares traded.

Patrys climbed 11.1 percent; Universal Biosensors was up 8.3 percent; Atomo rose 7.1 percent; Oncosil, Starpharma and Uscom improved six percent or more; Antisense and Next Science were up five percent or more; Kazia climbed 4.2 percent; Nova Eye and Prescient were up more than three percent; Avita, CSL, Nanosonics, Neuren and Opthea were up more than one percent; with Cochlear and Resmed up by less than one percent.

Impedimed led the falls, down 1.3 cents or 12.4 percent to 9.2 cents, with 7.1 million shares traded.

Actinogen, Alcidion, Micro-X, Proteomics and Volpara lost more than three percent; Clinuvel, Compumedics, Emvision, Genetic Signatures, Imugene and Resonance shed more than two percent; Amplia, Cyclopharm, Mesoblast, Polynovo and Pro Medicus were down one percent or more; with Telix down 0.1 percent.

[MONASH UNIVERSITY, QPEX BIOPHARMA](#)

Monash says that a 101-patient, randomized, controlled, phase I study showed ascending and multiple doses of its QPX9003 antibiotic were safe and well-tolerated.

Monash said the trial was conducted by the San Diego, California-based Qpex Biopharma, with the US Biomedical Advanced Research and Development Authority, showed that intravenous synthetic lipopeptide QPX9003 was well-tolerated in single dose escalation up to 400mg and multiple doses up-to 600mg each day for 14 days.

The University said that “no nephrotoxicity or other significant adverse events were observed and, importantly, no subjects discontinued the trial”.

“Based on its pharmaco-kinetic and safety profile and results in non-clinical models of infection, it is anticipated that QPX9003 can be safely dosed at levels that would be sufficient to achieve clinical efficacy and warrants further clinical development,” Monash University said.

Monash said that QPX9003 was used to treat gram-negative infections including those due to ‘superbugs’ resistant to many classes of antibiotics, which the World Health Organisation said was “urgently needed” to treat bacterial superbugs which had the potential to kill 10 million people a year by 2050.

Monash said data from the study was presented at ID (infectious diseases) Week in Washington, DC in October 2022.

The University said that QPX9003, which Qpex licenced from Monash in 2019, had been granted a qualified infectious disease product designation by the US Food and Drug Administration, which enabled “regulatory exclusivity extensions and eligibility for fast-track designation”.

Monash University antibiotic drug discovery program head Prof Jian Li said “these phase I results are very inspiring as the currently used treatments, polymyxin B and colistin, display significant toxicity issues in the clinic that have severely limited their use”.

“These results showing the safety and tolerability for QPX9003 at clinically relevant doses is critical and demonstrates that QPX9003 has the potential to be administered at significantly higher doses than polymyxin B and colistin without adverse effects,” Prof Li said.

[CARTHERICS PTY LTD, PETER MACCALLUM CANCER CENTRE](#)

Cartherics says it will work with Melbourne’s Peter MacCallum Cancer Centre to develop its Car-T-cell therapy, CTH-001, for cutaneous T-cell lymphoma.

The company did not disclose the terms of the agreement with the Cancer Centre but said it included clinical-scale manufacturing of its chimeric antigen receptor T-cell (Car-T) therapy, CTH-001, as well as a six-patient, phase I safety and tolerability trial in patients with refractory cutaneous T-cell lymphoma.

The Cancer Centre cellular immunotherapy director Prof Simon Harrison said patients with advanced cutaneous T-cell lymphomas “often have few treatment options left when their disease progresses, and experience lower quality of life and poor life expectancy”.

“We are impressed by the laboratory results achieved by Cartherics’ scientists,” Prof Harrison said. “We are eager to see if evidence of efficacy in pre-clinical models translates into an effective, safe therapy for patients using a highly innovative approach with autologous Car-T cells.”

Cartherics chief executive officer Prof Alan Trounson said that “in addition to their outstanding clinical research in oncology, Peter Mac, through Cell Therapies Pty Ltd, has substantial experience in manufacturing of cell therapies for cancer”.

Cartherics is a private company.

CORRECTION: RESPIRI

Last night's edition incorrectly assumed that Respi's "remote patient monitoring program" was a study.

Respi chief executive officer Marjan Mikel has told Biotech Daily that the program was "not a trial".

"This was the first patients to be enrolled in a commercial setting by doctors," Mr Mikel said.

Biotech Daily has despatched the Monday sub-editor and apologizes unreservedly for the error.

Respi was up 0.1 cents or 2.3 percent to 4.4 cents.

RADIOPHARM THERANOSTICS

Radiopharm says it will release 25,555,555 shares from ASX escrow on November 18, 2022.

According to its most recent filing, following the release of shares, Radiopharm will have 156,582,665 shares available for trading, with a further 100,000,000 shares remaining in ASX escrow.

Radiopharm fell 0.25 cents or 2.1 percent to 11.75 cents.

NUHEARA

Healthcare 2030, Bergen and Eugene Tablis say they have reduced their substantial holding in Nuheara from 15,260,648 shares (11.12%) to 13,240,000 shares (9.65%). The Boca Raton, Florida based Healthcare 2030, Bergen Global Opportunity Fund, Bergen Asset Management and Eugene Tablis said that between October 12, and November 1, 2022, they sold 2,020,648 shares for \$593,383, or 29.4 cents a share. Nuheara fell 2.5 cents or 7.25 percent to 32 cents with 1.2 million shares traded.

ALTHEA GROUP HOLDINGS

Althea says its annual general meeting will vote to issue 8,349,610 performance rights to managing-director Joshua Fegan.

Althea said shareholders would vote to issue 339,844 short-term and 509,766 long-term performance rights to Mr Fegan, vesting on 'absolute total shareholder return' and 7,500,000 long-term performance rights which would vest on the company achieving a minimum of \$100 million in revenue in any 12-month rolling period, all expiring on June 30, 2025.

The company said the meeting proposed to re-elect Alan Boyd as a non-executive director, approve the 10 percent placement facility and adopt the remuneration report.

The meeting will be held online on November 29, 2022 at 5pm (AEDT) at:

<https://us06web.zoom.us/j/4396532796>.

Althea was unchanged at 6.8 cents.